drugset / Trial / NCT00292942

Study of the Safety of Intravenous Artesunate

NCT00292942

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to establish the safety, tolerability, and pharmacokinetics of a multiple dose of the antimalarial drug artesunate.

Timeline

Start
2006-06-12
Primary completion
2007-01-17
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 2 mg/kg Intravenous
Subject Artesunate Small molecule 4 mg/kg Intravenous
Subject Artesunate Small molecule 8 mg/kg Intravenous

Indications